anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain a hepatic dysfunction preventive agent or a functional food, available from a raw material, derived from natural products and having high safety according to simple extracting operation without using chemicals dangerous to human bodies and effective in preventing and treating the hepatic dysfunction without any side effects. CONSTITUTION:A hepatic dysfunction preventive agent or a functional food having preventive action on hepatic dysfunction, containing a tea extract separated from tea leaves with water, an alcohol or a mixture solution thereof as an extracting solvent as an active ingredient and having the aforementioned effects is obtained. Furthermore, raw leaf parts may directly be used as the tea leaves or dried for use. Tea prepared by, as necessary, fermenting the tea leaves, then steaming, rolling or twisting and drying the tea leaves, e.g. green tea, &#39;SENCHA&#39; (green tea or middle grade), toasted green tea, oolong tea or black tea may be used. Extraction is carried out by adding 500-5000 pts.wt. solvent to, e.g. 100 pts.wt. dried tea leaves. The resultant extract solution is concentrated until the amount of the tea extract ingredient attains 30-50wt.%.
PROBLEM TO BE SOLVED: To obtain a saponin-containing extract having enhancing effect on immune strength, fatigue recovery effect, improving effect on blood flow, etc., useful as a health food, cosmetic, medicine, etc., by stirring Panax notoginseng in a solvent such as water, ethanol, etc., separating an extracted solution and concentrating the solution. SOLUTION: Panax notoginseng in an amount of 1 pt.wt. is mixed with 1-20 pts.wt. of a solvent containing one or more of water, ethanol, acetone and hexane, and stirred and an extracted solution is separated from a solid content. The extracted solution is concentrated by evaporating the solvent from the extracted solution until the volume of the extracted solution reaches &lt;=10 vol.% based on the amount of the solvent added, the solid content is separated and a supernatant liquid is concentrated by solvent evaporation until a saponin content reaches &gt;=5 wt.% to give the objective extract. The extraction temperature is preferably 30-50 deg.C and stirring is carried out for 2-24 hours. The concentration of the solvent can be performed by evaporating the solvent by an evaporator, an extraction pot with a condenser, etc.
MELANIN MODIFICATION COMPOSITIONS AND METHODS OF USE A method for the modification of melanin distribution, and the composition thereof to modify melanin distribution are disclosed. A method for the reduction of melanin distribution, and the composition thereof to reduce melanin distribution are disclosed. A representative composition comprises 4-ethoxybenzaldehyde and one or more additional active agents as well as a pharmaceutically acceptable carrier or excipient. Carriers and excipients may be formulated for topical administration. Compositions may also be formulated for transdermal administration. The compositions may be used for the prevention and treatment of pigmentation disorders, by way of non-limited example, post-inflammatory hyperpigmentation and others. The compositions may be used for lightening skin. WO 2012/094638 PCT/US2012/020550 Significant Reduction in Hyperpigmentation .A 9 -0-4% Hydroquinone m = 95 -a-Base +0.5% 4EB S o 90 U- 75 70 P&lt;O.001 compared to baseline for every time point Weeks
Method for preparing new espiro (dihydrobenzofuranpiperidines and pyrolroline) of formula (I), or a salt of addition of acid of them, pharmaceutically acceptable. X may be an atom of hydrogen or various types of radicals, &#34;n&#34; is the whole 1 or 2. The method is to hydrogen a compound of formula (II), where r is bencilo and provides a compound where r is hydrogen. Also understands to react a compound like the above, where r is hydrogen with different types of halures, providing the desired compound. This composite can also be obtained by reduction. This product has an application as analgesic, tranquilizing and as an intermediate for them. *formula* (Machine-translation by Google Translate, not legally binding)
The invention relates to non-steroidal gestagens of general formula (I), wherein R&lt;1&gt; and R&lt;2&gt; are the same or different and stand for a hydrogen atom, a C1-C5 alkyl group or a halogen atom, or together with the C atom of the chain stand for a ring with 3-7 units, R&lt;3&gt; means a C1-C5 alkyl group or a partially or fully fluorinated C1-C5 alkyl group, A stands for an optionally substituted mono or bi-cyclic aromatic ring, an ester group -COOR&lt;4&gt;, an alkenyl group -CR&lt;5&gt;=CR&lt;6&gt;R&lt;7&gt;, an alkinyl group -CCR&lt;5&gt; or for a partially or fully fluorinated C1-C5 alkyl group, B means a carbonyl group or a CH2 group and Ar is a ring system selected from the group of general partial formulae (2-11). When B represents a CH2 group in general formula (I), Ar additionally means a phenyl radical of partial general formula (12). The novel compounds display a very strong affinity to the gestagen receptor. They can be used on their own or in combination with oestrogen&#39;s in contraceptive preparations. They can also be used in the treatment of endometriosis. They can be used with oestrogen&#39;s in preparations for the treatment of gynaecological disorders. They can also be used to treat pre-menstrual complaints and in substitution therapy. Their androgen activity enables them to be used for male fertility control, male HRT and to treat andrological syndromes.
PURPOSE: To readily obtain the subject compound useful as an intermediate for cephalosporin antibiotic substances in a simple step by using a specific butenoic acid compound as a starting raw material. CONSTITUTION: A 2-azetidinyl-3,4-dihalogeno-2-butenoic acid compound of formula I [R&lt;1&gt; is H or a (protected)amino; R&lt;2&gt; is H or a lower alkoxy; R&lt;2&gt; is H or a protecting group of a carboxylic acid; W is an eliminative group; X and Y are each a halogen] is reacted with a thioacetic acid derivative capable of manifesting the basicity itself (e.g. potassium thioacetate) or a mixture of a base (e.g. sodium formate) with the thioacetic acid derivative or preferably the base in a hydrous organic solvent (e.g. tetrahydrofuran) at, e.g. ambient temperature to afford the objective derivative of formula II.
This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt&#39;s Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients.
PURPOSE:To measure surely a slight amt. of antigen by making use of the phenomenon that the clotting of a carrier sensitized with a complete antigen (referring to antigens except hapten) and a carrier sensitized with a single kind of monoclonal antibody against said antigen is prohibited by the antigen in a specimen (patient&#39;s serum, etc.). CONSTITUTION:A single monoclonal antibody is drawn from the cell obtd. by the cell fusion of the antibody forming cell obtd. by a subcutaneous injection of the complete antigen of hormone, alpha-fetoprotein, serum protein, etc. in an animal and a suitable myeloma cell and said antibody sensitized with, for example, polystyrene latex particles is prepd. On the other hand, the complete antigen sensitized with polystyrene latex particles is preliminarily prepd. Each one drop of said antigen-sensitized latex and anti-body sensitized latex is added to one drop of a prescribed dilute liquid of a patient&#39;s serum, etc. and both are uniformly mixed and after 2min, the presence or absence of the clotting image is observed. If there is an antigen in the serum, etc. or up to a certain dilution rate, the clotting image is not observed. The detection and determination of the slight antigen are thus made possible with good reproducibility in a short time.
PURPOSE:To obtain the titled derivative useful as a remedy for hyperlipemia, etc., by converting a specific derivative with a microorganism of Nocardia genus, etc. CONSTITUTION:An ML-236B derivative (A) consisting of a carboxylic acid having the structure of formula I, its pharmacologically permissible salt, its ester or its cyclized lactone is added at an amount of 0.01-0.5wt% to a cultured liquid obtained by culturing a microbial strain belonging to Nocardia genus, etc., (e.g. Nocardia sp. SANK 62781) for 1-3 days. The culture is contunued further for 3-5 days to effect the hydroxylation of the component A and to convert the component A to 3&#39;&#39;,6&#39;-dihydroxy-ML-236B derivative (B) consisting of a carboxylic acid having the structure of formula II, its pharmacologically permissible salt, its ester or its cyclized lactone. The converted culture liquid is filtered and the filtrate is extracted, separated and purified to obtain the component B.
What is claimed is a drug based on 3,3&#39;-diindolylmethane and β-cyclodextrin, wherein the ingredient ratio is as follows: 3,3&#39;-diindolylmethane 10-20 wt %, β-cyclodextrin 80-90 wt %. The method for producing said drug consists in dissolving β-cyclodextrin in water to give a solution concentration of 10-25% based on dry β-cyclodextrin. 3,3&#39;-diindolylmethane is added to the solution produced at the above-mentioned weight ratio. The solution is stirred, the resulting suspension is spray-dried using a gas at a temperature of 180°C, and the resulting dry product is sieved through a mesh to give a powder. A method for treating human papillomavirus (HPV)-associated cervical neoplasia consists in a single administration of a human papillomavirus vaccine to a female patient. The female patient is then subjected to a topical treatment using the drug comprising 3,3&#39;-diindolylmethane complexed with β-cyclodextrin. The invention makes it possible to increase the solubility of the drug in water and the stability thereof, and to eliminate a burning sensation and discomfort during treatment.
The invention relates to a nucleic acid molecule for preparing 3 &#39;introns and 5&#39; introns of circular RNA in vitro, and the sequence of the nucleic acid molecule is shown as SEQ ID NO.1 or SEQ ID NO. 2. The invention also provides 3 &#39;and 5&#39; introns for the in vitro preparation of circular RNA, which are truncated to the same sequence as SEQ ID NO.1 or SEQ ID NO.2, and have no overlapping regions. The invention also provides an in vitro preparation method for applying the intron to the circular RNA. According to the invention, by arbitrarily shearing two sequences SEQ ID NO.1 and SEQ ID NO.2, the 3 &#39;intron and the 5&#39; intron with high cyclization efficiency are obtained, and the linear mRNA can be cyclized efficiently and has less exogenous base residues. The obtained intron can be used for preparing circular RNA and further used for preparing mRNA vaccine.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an oil-in-water type emulsified cosmetic having excellent dispersibility of metal oxide powder, improved emulsifiability and stability with time and improved makeup lasting quality.  &lt;P&gt;SOLUTION: This oil-in-water type emulsified cosmetic comprises a component (a) of an organosilicone resin, a component (b) of an hydrophilic nonionic surfactant, a component (c) of a lipophilic nonionic silicone-based surfactant and a component (d) of metal oxide powder. In the oil-in-water type emulsified cosmetic, the component (a) is an acrylic-silicone graft copolymer. In the oil-in- water type emulsified cosmetic, the component (c) is a polyether modified organopolysiloxane. Any of the oil-in-water type emulsified cosmetics contains higher fatty acid soap as a component (e).  &lt;P&gt;COPYRIGHT: (C)2003,JPO
Present invention provides enhanced methods and improved devices to eliminate, reduce, destroy and/or inhibit undesired body fluid species, such as pathogen microbes and deteriorated or malignant cells in complex environments like blood, serum and other body fluids. In preferred embodiments, present invention provides an antimicrobial PDT treatment and devices that effectively inactivates, reduces and/or destroys both Gram (-) and Gram (+) bacteria in complex body fluids. Preferred device embodiments comprise guiding channels and at least one electromagnetic radiation source, arranged separately or in sequence. Preferably, laser device or LED-panels are used to deliver electromagnetic radiation to activate the photosensilizer. Electromagnetic radiation is preferably delivered intermittently with pulse width based on treatment parameters. When used with preferred photosensitizer composition based on Safranin O, preferred laser radiation wavelength is in the range of 500-580nm. Additionally, present invention diminishes adverse host&#39;s inflammatory responses by neutralizing the biological activity of pathogenic microorganism fragments and reducing and/or removing pathogenic microorganism fragments responsible for it.
A method, system and apparatus for use in treating a patient receiving a biological substance, such as a cancer vaccine, to optimize therapy and prevent an adverse response. This system employs surrogate markers or indicators including blood levels of the vaccine to determine the next required dose for a patient. Since the surrogate markers may be employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the vaccine&#39;s action. Given the effectiveness of the vaccine&#39;s action relative to the surrogate markers, a change in vaccine dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the vaccine dose change on the surrogate markers.
The present invention provides algin oligosaccharides having polymerized degree of 2-22 and the derivatives thereof, such algin oligosaccharides are made of mannuronic acid bonded by alpha-1,4 glycosidic bond. The derivatives which the reduced terminal in position-1 is carboxyl radical can be obtained by oxidation. The invention also provides the manufacture of algin oligosaccharides and the derivatives thereof, which includes the alginate solution in water reacts in the reactor under the condition of high press, 100-120C, pH2-6, for 2-6 hours, after the reaction completed, its pH value was adjusted to 7. The result oligosaccharides are oxidated in presence of the oxidant, and then produces the oxidated products. The algin oligosaccharides and the derivatives thereof of the invention can be used in the manufacture of medicaments for preventing Alzheimer&#39;s dementia. ® KIPO &amp; WIPO 2007
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an aqueous polymeric composition containing selected polymeric nanoparticles.  &lt;P&gt;SOLUTION: The selected polymeric nanoparticle contains at least one multiethylenically unsaturated monomer and at least one water-soluble monomer as polymer units and has an average diameter of 1-50 nm. The aqueous polymeric composition further contains 2nd particles such as pigment particles or 2nd polymer particles. The aqueous polymeric composition is useful for forming a coating having at least one improved property compared with a coating free from the selected polymeric nanoparticle. The aqueous polymeric composition is useful for the treatment of wood. The invention further provides a coating produced by using the aqueous polymeric composition.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
1. A method of administering taxane to a patient in need of treatment with taxane comprising administering a pharmaceutical composition over a period of less than an hour in an amount from about 75 to 300 mg/m2 wherein said pharmaceutical composition is liposomal encapsulated taxane or an antineoplastic derivative thereof. 2. The method of claim 1 wherein said taxane is selected from the group consisting of paclitaxel. 3. The method of claim 1 or 2 wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient. 4. The method of claim 1 or 2 wherein said pharmaceutical composition further comprises cardiolipin. 5. The method of claim 4 wherein said cardiolipin is selected from the group consisting of natural cardiolipin and synthetic cardiolipin. 6. The method of claim 1 or 2 wherein said amount of said taxane is about 135 mg/m&lt;2&gt;. 7. The method of claim 1 or 2 wherein said amount of said taxane is about 175 mg/m&lt;2&gt;. 8. The method of claim 1 or 2 wherein said amount of said taxane is about 250 mg/m&lt;2&gt;. 9. The method of claim 1 or 2 wherein said amount of said taxane is about 300 mg/m&lt;2&gt;. 10. The method of claim 1 or 2 wherein said liposomal encapsulated taxane is administered by intravenous infusion. 11. The method of claim 10 wherein said liposomal encapsulated taxane is administered over a period of 45 minutes. 12. The method of claim 10 wherein said administration of said liposomal encapsulated taxane is repeated at least once every 21 days. 13. The method of claim 1 or 2 wherein a patient in need of treatment with taxane is human, said liposomal encapsulated taxane being administering in less than 3 hours in quantity of from 90 to 300 mg/m&lt;2&gt;. 14. The method of claim 13 wherein said taxane is administered intravenously. 15. The method of claim 13 in which the liposomal taxane is administered as a single agent without pretreatment by steroids, antihistamines or other therapeutic agents. 16. The method of claim 13 in which substantial nonhematological toxicity is not induced. 17. The method of claim 13 in which substantial anaphylaxis is not induced. 18. The method of claim 13 in which said taxane is administered in less than 1 hour. 19. The method of claim 13 in which said taxane is administered in about 45 minutes. 20. The method of claim 13 further comprising repeating the step of administering rapidly a large quantity of liposomal taxane to a human without inducing substantial hematological or nonhematological toxicity. 21. The method of claim 20 wherein the repeating step occurs in 21 days. 22. A method of treating a human with taxane comprising intravenously administering to a human in about 45 minutes about 175 to 300 mg/m&lt;2&gt; of a liposomal taxane formulation that has a dose limiting toxicity of 18 at least about 300 mg/m&lt;2&gt; when administered in about 45 minutes.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide low viscosity oil-in-water type emulsion cosmetics generating no precipitation/coagulation with the time lapse, hardly causing viscosity increase and nondamaging good use feeling in long term preservation.  &lt;P&gt;SOLUTION: The low viscosity oil-in-water type emulsion cosmetics contain a modified titanium oxide in the oil phase and an alkyl-modified carboxyvinyl polymer and/or a carboxyvinyl polymer in the water phase, which modified titanium oxide is obtained by covering with silica the surface of titanium oxide containing practically no aluminum, and then imparting hydrophobicity. The titanium oxide is preferably rutile type. The total surface covering amount of the modified titanium oxide is preferably 1-20 mass% based on the titanium oxide. The viscosity of the cosmetics is suitability 500-8,000 mPa s. The cosmetics suitability contain practically no aluminum ion. The cosmetics suitability contain practically no zinc ion.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A key function of blood vessels, to supply oxygen, is impaired in tumors because of abnormalities in their endothelial lining. PHD proteins serve as oxygen sensors and may regulate oxygen delivery. Therefore the role of endothelial PHD2 in vessel shaping by implanting tumors in PHD2 mice was studied. Haplodeficiency of PHD2 did not affect tumor vessel density or lumen size, but normalized the endothelial lining and vessel maturation. This resulted in improved tumor perfusion and oxygenation, and inhibited tumor cell invasion, intravasation and metastasis. Haplodeficiency of PHD2 redirected the specification of endothelial tip cells to a more quiescent phenotype of a filopodia-lacking &#34;phalanx&#34; cell type. Without being bound to a particular mechanism, this transition could at least in part be explained by upregulation of (soluble) VEGFR-1 and VE-cadherin. Thus, decreased activity of an oxygen sensor in hypoxic conditions prompts endothelial cells to readjust their shape and phenotype to restore oxygen supply. I n hi biting P H D2 may offer alternative therapeutic opportunities for anti-cancer therapy, or other therapies where vascular normalization is beneficial.
Membranes formed by the coacervation of a material comprising at least one gelable hydrophilic colloid having amino groups and peptide linkages (e.g. proteins and polyamines) are treated with an aqueous solution of one or more of tannic acid, gallic acid or di-gallic acid to improve their physical characteristics, in particular their impermeability to fluids.  The membranes may be formed by simple or complex coacervation of one or more of the above colloids by any process and they may encapsulate solids, oils, hydrophilic liquid-in-oil and oil-in-hydrophilic liquid emulsions which may contain &#34;active&#34; ingredients which render the preparations suitable as fertilizers, plant growth hormone preparations, bactericides, pesticides, vitamin preparations, medicines and food additives. Treatment is preferably carried out subsequent to the gelling (e.g. by cooling) of the concervate under conditions of time and pH (generally acid) which allow the properties of the product to be varied.  Specified colloids of the above type are gelatine, fibrinogen, polylysine and polyornithine.  Specific examples relate to the treatment of: (a) particles of an aqueous solution of urea-in-corn oil emulsion encapsulated in gelatine with tannic acid, gallic acid and di-gallic acid; (b) a similar preparation comprising 1,2,4,5,6,7,8,8-octachloro-4,17-methano-3a ,4,7, p  7a -tetrahydroindan in place of the urea of (a) with tannic acid; (c) particles of an aqueous solution of chloral hydrate-in-mineral oil emulsion encapsulated in a complex coacervate of gelatine and styrene-maleic anhydride copolymer with tannic acid. Specifications 476,869, 483,550, 573,678, 751,600, 911,483, 929,401, 929,402, 929,403, 929,408, and 929,409 are referred to.
The disclosure provide compounds of Formula I and the pharmaceutically acceptable salts thereof. The variables, R 1 , R 2 , R 3 , X 1 , X 2 , and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore uncouplers that do not affect the plasma membrane potential. Compounds and salts of Formula I are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson&#39;s disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, compounds of Formula I are useful for increasing lifespan. Compounds and salts of Formula I are also useful for regulating glucose homeostasis or insulin action in a patient.